Biotechnology · Wayne, Pennsylvania, United States
$149.22
+0.42% (+$0.63)2026-08-25
Smart-Money SignalNeutral · 50/100— Insiders are net sellers over 90 days (-$1.7M, 19 sales vs 9 buys)
Net Income-$21.9M
EPS$-2.74
Market Cap$2.1B
Price Performance
Historical data including institutional events
Company Profile
W
Wesley Kaupinen
CEO & Executive Director
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
